Pyxis Oncology is trading at $3.31, +9.97% in pre-market on August 14, 2026, as investors appear focused on a private placement extending its operating runway into 2027.
- The financing provided approximately $50 million upfront and supports upcoming MICVO clinical milestones.
- The company reported a wider-than-expected $0.40-per-share second-quarter loss and zero milestone revenue.
- The prior session closed at $3.01, after declining 5.35%.